Effect of Statin Therapy on Age-Associated Changes in Physical Function Among Men With and Without HIV in the Multicenter AIDS Cohort Study

Abdo, Mona; Langan, Susan; MaWhinney, Samantha; Sun, Jing; Lake, Jordan E.; Palella, Frank J.; Kingsley, Lawrence; Brown, Todd T.; Erlandson, Kristine M.

doi:10.1097/qai.0000000000002579

Cited by 4 publications

(2 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study of Erlandson et al 23 analyzed the effects of 96 weeks of rosuvastatin on bone, muscle, and fat in PLWH (147 participants [115 males], 72 receiving rosuvastatin and 75 receiving placebo), and they reported a trend for increased lean body mass in the rosuvastatin arm (0.8% increase versus 0.5% decrease in the placebo arm). Abdo et al 22 determined the association between statin use and age-associated changes in physical function among men with (n = 1048) and without HIV (n = 973) and reported that consistent statin users do not seem to have a major impact on physical function (i.e. gait speed and handgrip strength).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Statin protects men but not women with HIV against loss of muscle mass, strength, and physical function: a pilot study

Cárdenas

Oliveira

Borsari

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Statins are cholesterol-lowering drugs commonly used among people with HIV, associated with an increased risk of myopathies. Considering that cardiovascular disease, statin therapy, and sarcopenia are independently prevalent in people with HIV, clarity on the potential benefits or harms of statin therapy on muscle health is useful to provide insight into ways to maximize skeletal muscle health and minimize CVD risk in this population. We aimed to study the effects of statin therapy on strength, muscle mass, and physical function parameters in people with HIV. This was a pilot cross-sectional study. People with HIV on continuous statin therapy (n = 52) were paired 1:1 according to age (people with HIV 53.9 ± 8.2 and people with HIV on statins 53.9 ± 8.4 years), sex, body mass index (Body mass index, people with HIV 28.6 ± 5.3 and people with HIV on statins 28.8 ± 6.3 kg/m2), and race with people with HIV not using statin (n = 52). Participants were evaluated for muscle strength (i.e. handgrip strength), lean and fat body mass (using bioelectric impedance analysis), and physical function (i.e. Short Physical Performance Battery—SPPB). Isokinetic strength and appendicular lean mass (using dual-energy X-ray absorptiometry), more accurate strength and body composition measures, were determined in 38% of the participants. Overall, statin usage does not exacerbated loss of muscle strength (32.2 ± 11.5 vs. 30.3 ± 9.6 kg, p > 0.05) muscle mass (7.6 ± 1.8 vs. 7.7 ± 1.1 kg/m2, p > 0.05), and impaired physical performance (10.1 ± 1.8 vs. 9.7 ± 2.1 points, p > 0.05) of PLWH. When analyzed by sex, men living with HIV on statins usage presented higher appendicular muscle mass (28.4 ± 3.1 vs. 26.2 ± 4.9 kg, p < 0.05) handgrip strength (42.1 ± 8.8 vs. 37.1 ± 8.3 kg, p < 0.05) and physical function through SPPB score (10.9 ± 1.3 vs. 9.5 ± 2.1, p < 0.05) than men living with HIV not on statins treatment. The same protection was not observed in women. This data was demonstrated when muscle mass and strength were determined clinically (i.e. handgrip strength and electrical impedance) and when more precise laboratory measurements of muscle mass and strength were conducted (i.e. isokinetic strength and DXA scans). Statin does not exacerbate muscle wasting, strength loss, or muscle dysfunction among people with HIV. Indeed, statins may protect men, but not woman with HIV against HIV and antiretroviral therapy-induced loss of muscle mass and strength.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Sarcopenia has been recently demonstrated to be high prevalent among PLWH 20 , 21 . However, the relationship between statin therapy, skeletal muscle outcomes, and physical function is still unclear, especially among PLWH 22 – 24 .…”

Section: Introductionmentioning

confidence: 99%